1st Floor, Unex House
132-134 Hills Road
Tel: 44-0-1223 341150
252 articles about Avita Medical
AVITA Medical to Attend the 2020 BTIG Healthcare Conference
AVITA Medical, a global regenerative medicine company, announced that management will attend the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from Wednesday, March 18, 2020 through Thursday, March 19, 2020 at The Cliff Lodge in Snowbird, Utah.
AVITA Medical Half-Year Financial Report for Fiscal 2020
AVITA Medical Limited announced that it filed with the Australian Securities Exchange its Appendix 4D – Half-Year Report for the six month period ended 31 December 2019.
AVITA Medical to Present at the Cowen 40th Annual Health Care Conference
AVITA Medical, a global regenerative medicine company, announced that management will present at the Cowen 40th Annual Health Care Conference in Boston.
AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update
AVITA Medical Limited, a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the fiscal second quarter ended 31 December 2019 in its Appendix 4C - Quarterly Cash Flow Report filed with the Australian Securities Exchange.
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo
AVITA Medical Limited announced that the U.S. Food and Drug Administration has approved the company’s Investigational Device Exemption application to conduct a feasibility study evaluating the safety and effectiveness of the RECELL® Autologous Cell Harvesting Device for repigmentation of depigmented lesions associated with stable vitiligo..
AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa
Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent-pending combined reprogramming and gene-editing methodology
AVITA Medical Names David McIntyre as Chief Financial Officer
Appointment Enhances Executive Leadership Team as AVITA Medical Broadens Access to Investors and Continues Growth Trajectory
AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development
AVITA Medical announced an institutional placement of A$120.0 million to fund pipeline development of new indications, including optimizing support for clinical trials and development projects, as well as the Company’s continued U.S. commercial growth strategy.
AVITA Medical Added to S&P/ASX 200 Index
AVITA Medical announced that the company will be added to the S&P/ASX 200 index, effective upon market open on 14 November 2019, two months after being added to the S&P/ASX 300 index.
AVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company Update
U.S. RECELL® System product sales of A$4.6M for fiscal first quarter, 60% growth quarter-over-quarter
AVITA Medical Announces Listing on Nasdaq
Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st
New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars
Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
AVITA Medical (ASX: AVH, OTCQX: AVMXY), announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application to conduct a pivotal trial evaluating the safety and effectiveness of the RECELL® Autologous Cell Harvesting Device (RECELL® System) in combination with meshed autografting for the treatment of acute full-thickness skin defect
AVITA Medical Added to the S&P/ASX 300 Index
AVITA Medical, a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019.
AVITA Medical Reports Fourth Quarter Fiscal 2019 Financial Results and Company Update
AVITA Medical, a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 30 June 2019, the fourth quarter of its fiscal 2019.
RECELL® System Feasibility Study Results for Treatment of Diabetic Foot Ulcers Presented at 11th Annual Congress of the Japanese Society of Limb Salvage & Podiatric Medicine
Innovative regenerative technology using patients’ own skin cells significantly reduced size of wounds caused by diabetic foot ulcers in all patients
AVITA Medical Announces RECELL® System Preliminary Data Focused on Vitiligo and Facial Acne Scars at the 24th Annual World Congress of Dermatology
Abstracts Showcase Research on Potential Use of RECELL® System in Regenerative Dermatology
Health Economic Model Published in Advances in Therapy Demonstrates Reduced Cost and Decreased Hospital Stay with the RECELL® System
AVITA Medical announced that the health economic model of the U.S. burn care pathway, developed in collaboration with Biomedical Advanced Research and Development Authority (BARDA) and IQVIA, has been published in the peer-reviewed journal, Advances in Therapy.
AVITA Medical Appoints Interim CFO
AVITA Medica announced that Dale A. Sander is resigning as Chief Financial Officer (CFO) to spend more time with his family on the east coast, effective immediately.
AVITA Medical to Present at RBC Capital Markets 2019 Healthcare Conference
AVITA Medical, a global regenerative medicine company, announced that management will present at the RBC Capital Markets 2019 Healthcare Conference in New York.